Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis

Show full item record



Permalink

http://hdl.handle.net/10138/204072

Citation

Saraswat , M , Joenvaara , S , Seppanen , H , Mustonen , H , Haglund , C & Renkonen , R 2017 , ' Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis ' , Cancer medicine , vol. 6 , no. 7 , pp. 1738-1751 . https://doi.org/10.1002/cam4.1107

Title: Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis
Author: Saraswat, Mayank; Joenvaara, Sakari; Seppanen, Hanna; Mustonen, Harri; Haglund, Caj; Renkonen, Risto
Contributor: University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, HUSLAB
Date: 2017-07
Language: eng
Number of pages: 14
Belongs to series: Cancer medicine
ISSN: 2045-7634
URI: http://hdl.handle.net/10138/204072
Abstract: Finland ranks sixth among the countries having highest incidence rate of pancreatic cancer with mortality roughly equaling incidence. The average age of diagnosis for pancreatic cancer is 69years in Nordic males, whereas the average age of diagnosis of chronic pancreatitis is 40-50years, however, many cases overlap in age. By radiology, the evaluation of a pancreatic mass, that is, the differential diagnosis between chronic pancreatitis and pancreatic cancer is often difficult. Preoperative needle biopsies are difficult to obtain and are demanding to interpret. New blood based biomarkers are needed. The accuracy of the only established biomarker for pancreatic cancer, CA 19-9 is rather poor in differentiating between benign and malignant mass of the pancreas. In this study, we have performed mass spectrometry analysis (High Definition MSE) of serum samples from patients with chronic pancreatitis (13) and pancreatic cancer (22). We have quantified 291 proteins and performed detailed statistical analysis such as principal component analysis, orthogonal partial least square discriminant analysis and receiver operating curve analysis. The proteomic signature of chronic pancreatitis versus pancreatic cancer samples was able to separate the two groups by multiple statistical techniques. Some of the enriched pathways in the proteomic dataset were LXR/RXR activation, complement and coagulation systems and inflammatory response. We propose that multiple high-confidence biomarker candidates in our pilot study including Inter-alpha-trypsin inhibitor heavy chain H2 (Area under the curve, AUC: 0.947), protein AMBP (AUC: 0.951) and prothrombin (AUC: 0.917), which should be further evaluated in larger patient series as potential new biomarkers for differential diagnosis.
Subject: Chronic pancreatitis
HDMSE
OPLS-DA
Pancreatic adenocarcinoma
Pancreatic cancer
TANDEM MASS-SPECTROMETRY
TISSUE FACTOR
SYSTEMIC INFLAMMATION
GEL-ELECTROPHORESIS
PROTEINS
BIOMARKER
PLASMA
QUANTIFICATION
ADENOCARCINOMA
COAGULATION
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Saraswat_et_al_2017_Cancer_Medicine.pdf 500.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record